<DOC>
	<DOC>NCT00931606</DOC>
	<brief_summary>Anemia can be caused by the chemotherapy treatment that is used to treat metastatic breast cancer. This study will be used to find out if ACE-011 can help treat chemotherapy induced anemia in patients with metastatic breast cancer.</brief_summary>
	<brief_title>Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Histologically confirmed diagnosis of breast cancer documented by cytology or biopsy Evidence of metastatic breast cancer with a minimum of one lesion per RECIST criteria Receiving a chemotherapy regimen including one of the following: anthracycline, taxane, gemcitabine or vinorelbine Planned treatment with the same chemotherapy regimen for a minimum of 9 weeks after Day 1 of study drug administration Hemoglobin value between ≥ 6.5 to &lt; 11.0 g/dL Life expectancy of ≥ 6 months Prior radiation therapy to &gt; 20% of the whole skeleton &gt; 5 prior chemotherapy treatment regimens for metastatic breast cancer Untreated CNS metastases (exception: CNS metastases treated with whole brain radiotherapy &gt; 6 months prior to randomization) Uncontrolled hypertension History of anemia as a result of inherited hemoglobinopathy History of autoimmune or hereditary hemolysis or gastrointestinal bleeding Pregnant or lactating</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>anemia</keyword>
	<keyword>metastatic</keyword>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
</DOC>